Who is sponsoring NCT03552861?

NCT03552861 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT03552861?

Interventions in NCT03552861: repetitive transcranial magnetic stimulation(rTMS).

What condition does NCT03552861 study?

NCT03552861 studies TMS Protocols in the Treatment of PD.

Is NCT03552861 still recruiting?

NCT03552861 is currently status unknown. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT03552861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment

Status unknown NA Last updated 13 January 2021

What this trial tests

NA trial testing repetitive transcranial magnetic stimulation(rTMS) in TMS Protocols in the Treatment of PD in 252 participants. Status unknown.

Timeline

15 August 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	252
Start date	15 August 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	10 locations across China

Drugs / interventions tested

repetitive transcranial magnetic stimulation(rTMS)

Conditions studied

TMS Protocols in the Treatment of PD — all drugs for TMS Protocols in the Treatment of PD →

Sponsor

Guangdong Provincial People's Hospital

Who can join

Adults 18 to 80, any sex, with TMS Protocols in the Treatment of PD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in Parkinson's disease patients with depression or cognitive impairment. The study consists of seven total visits to all. Compensation will be provided for each visit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel targeted therapies for Parkinson's disease.
Ntetsika T, Papathoma PE, Markaki I. · · 2021 · cited 78× · PMID 33632120 · DOI 10.1186/s10020-021-00279-2

Verify or expand the search:

Other trials of repetitive transcranial magnetic stimulation(rTMS)

Trials testing the same drug.

NCT06968026 — Effects of High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomi · NA · recruiting
NCT05590819 — rTMS in Chronic Poststroke Dysphagia · NA · unknown
NCT04707378 — Navigated Repetitive Transcranial Magnetic Stimulation for Parkinson's Disease With Depression or Cognitive Impairment · NA · unknown

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing